Search PubMed⌕ Search

Biomedical subjects

I Diamond

Publications and source records attributed to I Diamond.

179 records · Page 10Linked to original sources
PubMed1967

Oxidative phosphorylation in experimental bilirubin encephalopathy.

Mitochondria from the whole brain or cerebellum of newborn guinea pigs with experimental bilirubin encephalopathy failed to exhibit uncoupling of oxidative phosphorylation. The pigment concentrations required to initiate uncoupling in vitro are much higher than those found in the brain of neurotoxic animals.

Animals↗
PubMedDate not supplied

The determinants of delivery care in Kenya.

This paper examines the determinants of place of delivery and childbirth attendant in Kenya based on the 1993 Kenya Demographic and Health Survey data. The analysis utilizes multilevel logistic and multilevel multinomial regression models for the place of delivery and the type of childbirth attendant, respectively. The results show that delivery care in Kenya is determined by a wide range of factors: socioeconomic and cultural factors associated with the individual woman or her household, her demographic status or reproductive behavior relating to a specific birth, as well as availability and accessibility of health services within her community. In addition, a significant variation in delivery care behavior is observed between women and between communities, implying that there are unobserved factors within families and communities that have a significant effect on delivery care. The woman or family effect on delivery care is particularly strong, but varies by distance to the nearest delivery care facility.

Adolescent↗
PubMedDate not supplied

A therapeutic monitoring assay for N-methylformamide in human serum and urine.

This report describes a gas chromatographic procedure using a packed column and a flame ionization detector, which is suitable for the therapeutic monitoring of N-methylformamide (N-MF). N-MF is a polar compound that induces cancer cell maturation in vitro and exhibits antitumor activity with human tumors xenografted in nude mice. Toxicology studies with mice have shown this compound to be hepatotoxic. N-MF is currently undergoing Phase I clinical trial as an anticancer drug at this institution. In concert with its clinical trial, a method for the analysis of N-MF in biological fluids has been developed to study its pharmacokinetics. This method involves direct injection of urine or acetone-deproteinized serum onto a Chromosorb 103 column, using N,N-diethylformamide as an internal standard.

Chromatography, Gas↗
PubMedDate not supplied

An old look at quality assurance.

The medical-hospital-regulatory complex has perhaps gone too far in the amount of energy and money devoted to data gathering. If the intent of all of this effort is to benefit patient care, it seems fair to ask whether or not the right kind of data is being accumulated. This paper raises the question and points out that the appropriate questions were asked 85 years ago, and remain largely unanswered.

Data Collection↗
PubMedDate not supplied

The significance of beta-2 microglobulinuria associated with gentamicin therapy.

Gentamicin is a nephrotoxic agent known to damage the proximal tubule,--a site of low molecular weight (LMW) protein reabsorption and catabolism. The effect of gentamicin was investigated on three LMW proteins--amylase, light chains, and beta 2 microglobulin--and the effects were correlated on the latter to renal function as determined by creatinine clearance (GFR). The renal excretion of beta 2 microglobulin (beta 2M) was studied in 18 patients receiving gentamicin and eight control patients. Both gentamicin and control patients had similar mean ages and serum beta 2M. Twelve of the 18 gentamicin treated patients had marked increases in beta 2M excretion. The mean daily 2 beta microglobulin excretion for the gentamicin treated group was 10,511 microgram while that of the control group was 102 microgram. Serial determinations in 10 of the gentamicin treated patients revealed an increase in beta 2M excretion within 48 hours of starting therapy. No deterioration of GFR was seen in any patient. In four patients, beta 2M excretion decreased while still receiving gentamicin. The renal handling of amylase was found to be normal in four patients and mildly abnormal in three patients receiving gentamicin who also had increased beta 2M excretion. Urinary light chains were determined in four of these seven patients and found to be normal. It is concluded that gentamicin induces an early and often transient tubular proteinuria. This tubular proteinuria is not associated with clinical nephrotoxicity.

Aged↗
PubMedDate not supplied

Analysis of serum for gentamicin by radioimmunoassay.

A radioimmunoassay method for the determination of combined gentamicin isomers in serum has been adapted and tested. The procedure uses tritiated gentamicin, rabbit antiserum against a gentamicin-human albumin conjugate, and dextran-charcoal separation. The day-to-day coefficient of variation is 6 percent, and frozen samples are stable for at least one month. There was no cross reactivity of the antiserum with any of several tested antibiotics or with any of some tested commonly used non-antibiotic hospital pharmacy preparations. The results from the procedure correlated well with those of an enzymatic radioacetylation technique and, except for a significant incidence of "outliers", with a microbiological assay. As expected, patient serum values, both maximum and minimum, showed no correlation with dose size.

Biological Assay↗